OVIDOvid Therapeutics Inc.
$2.34+40% 1Y
$2.34
$1.2052 weeks$2.96
Price
+40%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, a flag to check, growth fading, the market undecided.
P/En/a
Market value$435.8M
1 year+40%
5 years-31%
Charts
As reported to the SEC, without any scoring.
Ovid Therapeutics Inc. (OVID) reported revenue of $733K in Q2 2026 (quarter ended Jun 30, 2026), down 88% from the same quarter a year earlier. That came with net loss of $15M. For the full year FY2025, revenue was $7.3M (+1181% year on year) and net income −$17M.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 13, 2026Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results.Material event (exhibits only) · press release
- Jul 8, 2026Executive Transition On July 5, 2026, Ovid Therapeutics Inc. (the “Company”) and Jeffrey Rona, who served as the Company’s Chief Business and Financial Officer, principal financial officer, principal accounting officer and secretary, mutually agreed to Mr. Rona’s transition from such roles with the Company, effective …Director or officer change · Form 8-K
- Jun 3, 2026On May 29, 2026, the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”) approved, effective as of June 15, 2026, an increase in the size of the Board and, upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), the appointment of Anna …Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.